| 46.99 0.01 (0.02%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.91 | 1-year : | 64.14 |
| Resists | First : | 47.02 | Second : | 54.91 |
| Pivot price | 46.9 |
|||
| Supports | First : | 46.71 |
Second : | 46.52 |
| MAs | MA(5) : | 46.98 |
MA(20) : | 46.86 |
| MA(100) : | 47.22 |
MA(250) : | 40.67 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 90.3 |
D(3) : | 89.6 |
| RSI | RSI(14): 63.7 | |||
| 52-week | High : | 62 | Low : | 28.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SWTX ] has closed below upper band by 27.5%. Bollinger Bands are 96.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 47.03 - 47.26 | 47.26 - 47.46 |
| Low: | 46.43 - 46.7 | 46.7 - 46.93 |
| Close: | 46.59 - 47 | 47 - 47.36 |
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Thu, 10 Jul 2025
Principal Financial Group Inc. Decreases Stock Position in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
Tue, 01 Jul 2025
SpringWorks Therapeutics, Inc.(NasdaqGS: SWTX) dropped from S&P TMI Index - MarketScreener
Thu, 26 Jun 2025
SpringWorks Merger with Merck Approved by Shareholders - TipRanks
Wed, 30 Apr 2025
Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks - Reuters
Mon, 28 Apr 2025
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks - GlobeNewswire
Mon, 28 Apr 2025
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 75 (M) |
| Shares Float | 74 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 87.4 (%) |
| Shares Short | 6,380 (K) |
| Shares Short P.Month | 5,960 (K) |
| EPS | -3.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | -115.6 % |
| Operating Margin | -164.1 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -51.6 % |
| Qtrly Rev. Growth | 133.6 % |
| Gross Profit (p.s.) | 2.71 |
| Sales Per Share | 2.91 |
| EBITDA (p.s.) | -3.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -165 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -13.79 |
| PEG Ratio | 0 |
| Price to Book value | 8.43 |
| Price to Sales | 16.11 |
| Price to Cash Flow | -21.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|